Antimicrobial resistance

In May 2016, WHO and the Drugs for Neglected Diseases initiative (DNDi) launched the Global Antibiotic Research and Development Partnership (GARDP) – for the development of new antibiotic treatments and to ensure access and appropriate use of antibiotics. 

An informal Member States Consultation was also held in November 2017 and again in October 2018 to discuss the development of the Global Framework for Development and Stewardship to Combat Antimicrobial Resistance.

WHO will continue to undertake the annual clinical and preclinical pipeline analysis and has developed missing target product profiles, to complement these activities.

In May 2018, the Global Antimicrobial Resistance Research and Development Hub (Global AMR R&D Hub) was launched. It aims to further improve the coordination of international efforts and initiatives to tackle AMR while further increasing investments into R&D for AMR.

The UN Interagency Coordination Group (IACG) on AMR, in its report to the Secretary General of the UN on 19 April 2019 calls on public, private and philanthropic research funders and other stakeholders to build on current R&D efforts for new antimicrobials.